[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Wu TT, Swisher SG: The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer; 2006 Sep 1;107(5):967-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.
  • BACKGROUND: Tumor viability assessed by pathologic analysis of resected specimens in patients with preoperatively treated esophageal adenocarcinoma (EAC) is a prognostic indicator.
  • The feasibility of induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) and surgery for patients with locoregionally advanced EAC has been demonstrated.
  • METHODS: The authors retrospectively reviewed 247 consecutive patients with EAC who presented for planned surgery after treatment with either CCRT or CRT from January 1997 through August 2003.
  • Pathologic tumor response, overall survival, and disease-free survival were assessed according to treatment.
  • Subset analysis of patients with clinical Stage III/IVA disease showed a median overall survival of 51 months with a 3-year overall survival rate of 58% in the CCRT group and a median overall survival of 20 months with a 3-year overall survival rate of 28% in the CRT group (HR, 0.57; P = .019).
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2007 Apr 1;109(7):1448-9; author reply 1449 [17328063.001]
  • (PMID = 16874819.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Kuwahara A, Yamamori M, Nishiguchi K, Okuno T, Chayahara N, Miki I, Tamura T, Kadoyama K, Inokuma T, Takemoto Y, Nakamura T, Kataoka K, Sakaeda T: Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma. Int J Med Sci; 2010;7(1):48-54
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma.
  • OBJECTIVE: The effects of dose-escalation of 5-fluorouracil (5-FU) on the clinical outcome and pharmacokinetics of 5-FU were investigated in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma.
  • METHODS: Thirty-five patients with Stage III/IVa were enrolled, who were treated with a definitive 5-FU/cisplatin-based chemoradiotherapy.
  • A course consisted of continuous infusion of 5-FU at 400 mg/m(2)/day (the standard dose group, N=27) or 500-550 mg/m(2)/day (the high dose group, N=8) for days 1-5 and 8-12, infusion of cisplatin at 40 mg/m(2)/day on days 1 and 8, and radiation at 2 Gy/day on days 1 to 5, 8 to 12, and 15 to 19, with a second course repeated after a 2-week interval.
  • RESULTS AND CONCLUSIONS: No patient with Stage IVa achieved a complete response in the standard dose group, whereas a complete response was observed at a rate of 50% in the high dose group, and this can be explained by a higher plasma concentration of 5-FU.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy. Fluorouracil / administration & dosage. Fluorouracil / pharmacokinetics
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / blood. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Asian Continental Ancestry Group. Circadian Rhythm / drug effects. Circadian Rhythm / physiology. Cisplatin / administration & dosage. Cisplatin / adverse effects. Dose-Response Relationship, Drug. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1999 May 5;281(17):1623-7 [10235156.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):277-84 [8996153.001]
  • [Cites] Ther Drug Monit. 2005 Jun;27(3):369-74 [15905809.001]
  • [Cites] Jpn J Clin Oncol. 2005 Jun;35(6):316-23 [15961436.001]
  • [Cites] Chronobiol Int. 2005;22(4):741-54 [16147904.001]
  • [Cites] Am J Clin Oncol. 2005 Dec;28(6):555-9 [16317263.001]
  • [Cites] Radiat Med. 2006 Jan;24(1):65-71 [16715664.001]
  • [Cites] J Gastroenterol. 2006 May;41(5):425-32 [16799883.001]
  • [Cites] Hepatogastroenterology. 2006 Nov-Dec;53(72):863-8 [17153442.001]
  • [Cites] Am J Clin Oncol. 2007 Jun;30(3):252-7 [17551301.001]
  • [Cites] Adv Drug Deliv Rev. 2007 Aug 31;59(9-10):1015-35 [17692427.001]
  • [Cites] Ther Drug Monit. 2008 Aug;30(4):497-503 [18641541.001]
  • [Cites] Eur J Pharm Sci. 2009 Jan 31;36(1):20-38 [19041394.001]
  • [Cites] Dis Esophagus. 2008;21(5):430-6 [19125797.001]
  • [Cites] Adv Drug Deliv Rev. 2009 May 20;61(5):388-401 [19135108.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2915-21 [10561371.001]
  • [Cites] Jpn J Clin Oncol. 2001 Sep;31(9):419-23 [11689594.001]
  • [Cites] Chronobiol Int. 2002 Jan;19(1):177-89 [11962674.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):18-24 [12556953.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2697-702 [12860946.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):425-33 [12957254.001]
  • [Cites] Cancer Res. 1990 Jan 1;50(1):197-201 [2293556.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] Jpn J Clin Oncol. 1993 Aug;23(4):250-7 [8411739.001]
  • [Cites] JAMA. 1996 Aug 28;276(8):637-9 [8773637.001]
  • [Cites] Jpn J Clin Oncol. 2004 Oct;34(10):615-9 [15591460.001]
  • (PMID = 20151048.001).
  • [ISSN] 1449-1907
  • [Journal-full-title] International journal of medical sciences
  • [ISO-abbreviation] Int J Med Sci
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2820235
  • [Keywords] NOTNLM ; 5-fluorouracil / circadian rhythm / dose-escalation / esophageal squamous cell carcinoma / plasma concentration
  •  go-up   go-down


3. Knox JJ, Wong R, Visbal AL, Horgan AM, Guindi M, Hornby J, Xu W, Ringash J, Keshavjee S, Chen E, Haider M, Darling G: Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. Cancer; 2010 Sep 1;116(17):4023-32
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.
  • BACKGROUND: Esophagectomy for locally advanced esophageal cancer (LAEC) is associated with limited survival.
  • Trimodality therapy yields a small survival advantage, with cisplatin and 5-fluorouracil regimens most frequently studied.
  • METHODS: Patients with LAEC of the thoracic esophagus or gastroesophageal junction underwent chemotherapy with preoperative irinotecan (65 mg/m(2)) plus cisplatin (30 mg/m(2)) on Weeks 1, 2, 4, 5, 7, and 8 with concurrent conformal radiotherapy (40 grays [Gy]/20 fractions during Weeks 4-7) and external beam boost (10 Gy/5 fractions at Week 8).
  • Nineteen patients had American Joint Committee on Cancer stage II, 22 had stage III, and 11 had stage IVA disease.
  • Grade 3 to 4 toxicity (graded according to the National Cancer Institute Common Toxicity Criteria 2.0) during induction included neutropenia (36%), febrile neutropenia (8%), diarrhea (10%), and esophagitis (4%).
  • Three patients withdrew from treatment due to toxicity.
  • There was 1 treatment-related death.
  • Median and 3-year overall survival for patients receiving trimodality therapy was 36 months and 51%, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Esophageal Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy. Esophagectomy. Esophagogastric Junction. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Radiotherapy, Conformal

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Cancer 2010. (c) 2010 American Cancer Society.
  • (PMID = 20533506.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


Advertisement
4. Morimoto J, Oohira M, Kubo N, Tanaka H, Dan N, Muguruma K, Yashiro M, Sawada T, Yamashita Y, Nishiguchi Y, Hirakawa K: [A case of stage IV advanced esophageal cancer with a long term survival by radiation therapy combined with nedaplatin and 5-FU chemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2436-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IV advanced esophageal cancer with a long term survival by radiation therapy combined with nedaplatin and 5-FU chemotherapy].
  • Various examinations revealed an esophageal cancer with direct invasion to the left main bronchus (cT4, N2 (104R, 106recR), M0, Stage IVa) and gastric cancer (cT2, N0, M0, Stage IB).
  • The patient was given preoperative chemoradiotherapy (40 Gy/20 fr with CDGP 10 mg/body day 1-5, 8- 12, 15-19 and 5-FU 250 mg/body day 1-5, 8-12, 15-19).
  • After the chemoradiotherapy, we estimated that the esophageal cancer was down stage (cT4-->T3), and that a curative operation was possible.
  • Pathological therapeutic evaluation of the esophageal cancer was complete response (CR) and the gastric cancer was T2, N0.
  • Adjuvant chemotherapy was undergone with S-1.
  • The patient is still alive without recurrence 5 years and 2 months after the first treatment.
  • Radiation therapy combined with nedaplatin and 5-FU is a safe and effective method for treating cT4 advanced esophageal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Combined Modality Therapy. Esophagectomy. Fluorouracil / administration & dosage. Gastrectomy. Humans. Male. Neoplasm Staging. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / therapy. Organoplatinum Compounds / administration & dosage. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037448.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Zhang J, Chen HQ, Zhang YW, Xiang JQ: Adjuvant chemotherapy in oesophageal cancer: a meta-analysis and experience from the Shanghai Cancer Hospital. J Int Med Res; 2008 Sep-Oct;36(5):875-82
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in oesophageal cancer: a meta-analysis and experience from the Shanghai Cancer Hospital.
  • Whether adjuvant chemotherapy increases survival of oesophageal cancer patients has been widely debated.
  • The present study used meta-analysis software to combine data from six studies up to July 2007 that were found and selected as suitable, comprising a total of 1001 oesophageal cancer patients.
  • The results indicated that adjuvant chemotherapy did not significantly improve outcome in oesophageal cancer patients.
  • A trend towards improved outcome from adjuvant chemotherapy was found in lymph node-positive patients, but did not reach significance.
  • In our own study including 270 oesophageal cancer patients, adjuvant chemotherapy did not improve overall patient survival, but did improve survival for patients with metastases in cervical and/or celiac lymph nodes (stage IVa).
  • Although our study had the largest patient sample, more prospective clinical trials with large numbers of patients are necessary to confirm the value of adjuvant chemotherapy in stage IVa patients.
  • [MeSH-major] Chemotherapy, Adjuvant. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cancer Care Facilities. China. Disease-Free Survival. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18831879.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 18
  •  go-up   go-down


6. Shimakawa T, Naritaka Y, Asaka S, Isohata N, Yamaguchi K, Murayama M, Konno S, Katsube T, Ogawa K, Ide H: A case of esophageal cancer with multiple lymph node metastases which responded to neoadjuvant chemotherapy (DCF therapy). Anticancer Res; 2010 Jan;30(1):221-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of esophageal cancer with multiple lymph node metastases which responded to neoadjuvant chemotherapy (DCF therapy).
  • It is difficult to perform radical surgery for esophageal cancer with multiple lymph node metastases.
  • Therefore, effective neoadjuvant adjuvant treatment is necessary to achieve successful radical resection.
  • The use of neoadjuvant chemotherapy of docetaxel, cisplatin (CDOP) and 5-fluorouracil (5-FU) (DCF) in an advanced case is reported.
  • The patient (a 67-year-old female) was diagnosed with esophageal cancer, T3, N4, M0, stage IVa with a large number of lymph node metastases in the mediastinum and in the abdominal cavity.
  • Neoadjuvant DCF chemotherapy was initiated in August 2006.
  • A complete response of the lymph node metastases in the abdominal cavity and a partial response of the esophageal lesion were achieved.
  • The surgical procedure included a right thoracolaparotomy followed by a subtotal excision of the esophagus and two-field lymph node dissection.
  • The cancer was diagnosed to be moderately differentiated squamous cell cancer, pT2, pN4(3c) and pstage IVa.
  • The histological efficacy of the chemotherapy was determined to be grade 1a.
  • Two additional courses of DCF therapy were administered followed by postoperative adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Neoadjuvant Therapy. Neoplasm Staging. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150639.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Watanabe T, Chinen T, Nakachi N, Nakamoto M, Uchima N, Hirata T, Hokama A, Kinjo N, Kinjo F, Fujita J: [Recurrent esophageal cancer with complete response to TS-1 chemotherapy]. Gan To Kagaku Ryoho; 2007 Mar;34(3):419-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent esophageal cancer with complete response to TS-1 chemotherapy].
  • An 80-year-old man was admitted to our hospital for treatment of recurrent esophageal cancer in December, 2004.
  • He was diagnosed as having esophageal cancer of stage IVa (T2N4M0) in October, 2002, and he received chemoradiotherapy (nedaplatin (CDGP)/5-fluorouracil (5-FU) total 6 course+60 Gy).
  • On admission, because of renal disturbance and dementia with advanced age, we chose chemotherapy with TS-1 (100 mg/body/day, three weeks of administration, then two weeks of withdrawal).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy. Lymph Nodes / pathology. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged, 80 and over. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Humans. Lymphatic Metastasis. Male. Quality of Life. Remission Induction

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353634.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


8. Motoyama S, Hosono Y, Maruyama K, Okuyama M, Saito R: [A case of thoracic esophageal cancer with invasion of the main bronchus in which long-term survival with high quality of life was achieved through chemoradiotherapy, esophageal bypass and then additional chemotherapy]. Gan To Kagaku Ryoho; 2007 Dec;34(13):2283-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of thoracic esophageal cancer with invasion of the main bronchus in which long-term survival with high quality of life was achieved through chemoradiotherapy, esophageal bypass and then additional chemotherapy].
  • We administered chemoradiotherapy consisting of 5-fluorouracil and cisplatin combined with radiation (59.8 Gy) to a patient with locally advanced esophageal cancer (T4 (left main bronchus) N2M0, stage IVa).
  • The cancer disappeared completely after the chemoradiotherapy.
  • However, because an esophagobronchial fistula occurred, an esophageal bypass was performed according to the method of Postlethwait.
  • Thereafter, multiple lung metastases appeared, which we treated with paclitaxel 120-210 mg/body during a total of 23 chemotherapy treatments over more than 2 years.
  • For a lesion that recurred in a cervical paraesophageal lymph node, we administered 60 Gy of radiation.
  • With these combined therapies, this patient survived 50 months as an outpatient with high quality of life.
  • It is difficult to treat patients in whom there is direct invasion of the trachea or main bronchus by esophageal cancer, and we cannot generalize about the best treatment for these patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bronchial Neoplasms / pathology. Esophageal Neoplasms / therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Invasiveness. Paclitaxel / administration & dosage. Quality of Life

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079631.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Ohyama M, Ikeda H, Yamaguchi K, Okabe M, Morimoto Y, Kawamoto K, Sano K, Paku T, Imai S, Yoshida Y, Ito T, Ogasahara K: [Complete response in a case of advanced unresectable esophageal cancer treated by chemoradiation therapy and S-1+CDDP chemotherapy]. Gan To Kagaku Ryoho; 2010 Feb;37(2):299-302
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete response in a case of advanced unresectable esophageal cancer treated by chemoradiation therapy and S-1+CDDP chemotherapy].
  • We report a 37-year-old woman who complained of chest discomfort as of August 2004, and was found to have advanced esophageal cancer in the upper thoracic area in December 2004.S he was diagnosed as Stage IVa (T4N1M0) because chest computed tomography (CT) indicated trachea invasion and lymph node metastasis.
  • We diagnosed it to be a case of unresectable esophageal cancer, and she underwent chemoradiation therapy.
  • Following this, 10 courses of the treatment with CDDP alone (CDDP 10 mg/weekly) were continued until the appearance of renal dysfunction.
  • The treatment is currently ongoing, and no recurrence or metastases had occurred as of March 2009.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Carcinoembryonic Antigen / blood. Combined Modality Therapy. Drug Combinations. Female. Humans. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154489.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Yoon HH, Gibson MK: Combined-modality therapy for esophageal and gastroesophageal junction cancers. Curr Oncol Rep; 2007 May;9(3):184-92
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined-modality therapy for esophageal and gastroesophageal junction cancers.
  • The optimal management of locoregional esophageal cancer is controversial.
  • Preoperative concomitant chemoradiotherapy (two courses of cisplatin and 5-fluorouracil plus 50 Gy of radiation) may provide benefit in survival and local control compared with surgery alone and is a reasonable alternative to surgery alone in stages IIB, III, and possibly stage IVa disease.
  • Preoperative chemotherapy without radiation also provides a survival benefit compared with surgery alone, but data are insufficient to conclude it is superior to preoperative chemoradiotherapy.
  • Control of distant disease remains a problem with preoperative chemotherapy and preoperative chemoradiotherapy.
  • [MeSH-major] Esophageal Neoplasms / therapy. Esophagogastric Junction / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Esophagectomy. Fluorouracil / administration & dosage. Humans. Neoadjuvant Therapy. Neoplasm Metastasis. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1513-30 [12496039.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2347-54 [15160337.001]
  • [Cites] Gut. 2004 Jul;53(7):925-30 [15194636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):120-7 [12909224.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Oct 19;(4):CD001799 [16235286.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] World J Surg. 1992 Nov-Dec;16(6):1104-9; discussion 1110 [1455880.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1779-84 [8137201.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):279-86 [11466680.001]
  • [Cites] Am J Surg. 2003 Jun;185(6):538-43 [12781882.001]
  • [Cites] Hepatogastroenterology. 1994 Aug;41(4):391-3 [7959579.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):659-68 [16129366.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1349-55 [16130133.001]
  • [Cites] J Thorac Cardiovasc Surg. 1988 Aug;96(2):242-8 [2456424.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001556 [16855972.001]
  • [Cites] J Surg Oncol. 1994 Jul;56(3):191-7 [7518020.001]
  • [Cites] JAMA. 1999 May 5;281(17):1623-7 [10235156.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):328-34 [12738305.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4330-7 [15781882.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):868-76 [10673530.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1820-8 [8859198.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Arch Surg. 1992 Dec;127(12):1446-50 [1365692.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2165-74 [11391598.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] J Gastrointest Surg. 2005 Jul-Aug;9(6):794-802 [16187480.001]
  • (PMID = 17430689.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 37
  •  go-up   go-down


11. Suzuki S, Goto M, Okamoto T, Tomita I, Murayama A, Sawa M, Noguchi Y, Hoshikawa Y, Shimizu A: [A case of small cell carcinoma of the esophagus with SIADH]. Gan To Kagaku Ryoho; 2010 Jan;37(1):123-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of small cell carcinoma of the esophagus with SIADH].
  • The patient was a 63-year-old male admitted for further evaluation of the bleeding esophageal tumor.
  • Endoscopic biopsy revealed small cell carcinoma.
  • Under diagnosis of small cell carcinoma of the esophagus at Stage IVa, neoadjuvant chemotherapy with FP (5-FU+CDDP) was given.
  • Immediately after fluid load, levels of serum sodium decreased to 117 mEq/L and persisted during chemotherapy treatment despite aggressive corrections.
  • [MeSH-major] Carcinoma, Small Cell / complications. Esophageal Neoplasms / complications. Inappropriate ADH Syndrome / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Esophagectomy. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087045.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Khushalani NI, Miecznikowski J, Wang D, Nowak N, Nava H, Nava ME, Tan W, Iyer R, Yang G, Pendyala L: Capecitabine (C), oxaliplatin (OXP), and radiation (RT) in resectable esophagus cancer (EC): A phase II trial with gene expression profiling (GEP). J Clin Oncol; 2009 May 20;27(15_suppl):e15543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine (C), oxaliplatin (OXP), and radiation (RT) in resectable esophagus cancer (EC): A phase II trial with gene expression profiling (GEP).
  • : e15543 Background: Novel chemotherapy regimens in combination with RT aim to improve the pathologic complete response (pCR) in EC.
  • Following our dose-finding phase I study, the present phase II neo-adjuvant (NA) EC trial was designed to examine the pCR rate using C, OXP and RT, with secondary end-points of evaluating toxicity, quality of life, and GEP of tumor tissue for correlation to therapeutic response.
  • METHODS: EC patients (PTS) with stages II-IVa, adequate organ function and performance status (ECOG 0-1) were eligible.
  • Treatment consisted of OXP, 85mg/m<sup>2</sup> iv on days 1, 15 and 29, C (oral or enteral tube) 625 mg/m<sup>2</sup> bid on days of RT, and 50.4 Gy RT (3-D conformal) in 28 fractions, followed by an esophagectomy (E) 4-6 weeks later.
  • GEP using Agilent microarrays was conducted on primary tumor tissue pre-treatment (Rx), day (D) 17 and at E; > 50% viable tumor cells were required.
  • Clinical stage: II (3), III (13) and IVa (4).
  • 18 PTS have completed NA therapy; Grade 4 toxicity includes anemia (1), lymphopenia (2); grade 3 toxicity includes esophagitis (1), pneumonia (1), wound infection (1), anastomotic leak (2), esophageal fistula (1), bowel obstruction (1), fatigue (1), hyperbilirubinemia (1), elevated ALT, AST (1 & 2, respectively), hypoalbuminemia (3), OXP hypersensitivity (2) & leucopenia (1).
  • The exploratory GEP analysis may provide insight on predicting response to NA therapy.
  • Acknowledgement: The study was approved and funded by the National Comprehensive Cancer Network (NCCN) from general research support provided by Roche Laboratories, Inc.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962302.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Hilbig A, Stieler J, Pelzer U, Okenga J, Hintze R, Roll L, Gövercin M, Arning M, Riess H, Oettle H: Phase II study of gemcitabine, cisplatin, folinic acid (FA) and infusional 5-fluorouracil (5-FU) in patients with inoperable esophageal cancer (IEC). J Clin Oncol; 2004 Jul 15;22(14_suppl):4238

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of gemcitabine, cisplatin, folinic acid (FA) and infusional 5-fluorouracil (5-FU) in patients with inoperable esophageal cancer (IEC).
  • : 4238 Background: Our previous phase I study has shown that combination chemotherapy with gemcitabine, 5-FU/FA, and cisplatin (GFFC) is feasible and has encouraging activity in IEC.
  • Therefore, we initiated a multicenter phase II study of outpatient GFFC treatment for IEC.
  • METHODS: A two-stage design was used, 11 or more of the first 25 evaluable patients (pts) were required to achieve at least SD to complete enrolment to a total of 66 pts.
  • Treatment consists of cisplatin 30 mg/m<sup>2</sup> (90 min), gemcitabine 1000 mg/m<sup>2</sup> (30 min), FA 200 mg/m<sup>2</sup> (30 min), and 5-FU 750 mg/m<sup>2</sup> (24h) on days 1 + 8 q3w.
  • Two pts had stage IIB, 17 stage III, 9 stage IVA and 13 stage IVB.
  • We therefore opened the second stage of our study, and recruitment is ongoing.
  • Updated results will be available at the time of the meeting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014021.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Takeno A, Tamura S, Miki H, Ono H, Uchiyama C, Kanemura T, Yanai A, Kobayashi M, Yoshioka Y, Suzuki R, Nakahira S, Nakata K, Okamura S, Takeda Y: [Successful treatment of advanced esophageal cancer with lymph node metastases by docetaxel, cisplatin and 5-FU followed by salvage lymphadenectomy--a case report]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2382-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment of advanced esophageal cancer with lymph node metastases by docetaxel, cisplatin and 5-FU followed by salvage lymphadenectomy--a case report].
  • We present a case of advanced esophageal cancer with multiple lymph node metastases successfully treated by combination therapy of docetaxel, cisplatin and 5-FU (DCF) followed by salvage lymphadenectomy.
  • The patient was a 60-year-old female with the diagnosis of squamous cell carcinoma of the middle thoracic esophagus.
  • The clinical stage diagnosis was cT2N4M0, cStage IVa.
  • Systemic chemotherapy with DCF was started as the initial treatment.
  • Combination therapy of DCF and salvage lymphadenectomy is potentially effective for advanced esophageal cancer with lymph node metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / pathology. Esophageal Neoplasms / therapy. Lymph Node Excision. Lymphatic Metastasis. Salvage Therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Middle Aged. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224580.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Ota Y, Minamide J, Takata K, Aoyama N: [A case of advanced esophageal cancer that has come back eight years after combined modality therapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2442-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced esophageal cancer that has come back eight years after combined modality therapy].
  • In February 1992, right thoracotomy subtotal thoracic esophagectomy was performed after performing preoperative chemotherapy (FP therapy) for advanced esophageal cancer for two courses.
  • The pathological diagnosis was Mt, mod. diff. sqcc, mp, n4 (#2: 1/13, #9: 3/4), ly2, v0, stage IVa.
  • As a postoperative adjuvant therapy, FP therapy was performed for two courses and we took a wait-and-see approach as an outpatient since then.
  • As we found lymph node metastasis surrounding the root of celiac artery and right renal vein by an abdominal CT in October 1999, nedaplatin+5-FU therapy was performed for 5 courses/24 weeks as second-line chemotherapy, and furthermore, a radiation therapy, linac 50 Gy was performed.
  • The involved lymph node was reduced and the therapy evaluation was CR.
  • We have experienced a case of advanced esophageal cancer that has come back eight years after combined modality therapy, and after that, the patient could obtain a long-term survival with a marked effect of chemotherapy.
  • [MeSH-major] Esophageal Neoplasms / pathology. Esophageal Neoplasms / therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Fluorouracil. Humans. Neoplasm Recurrence, Local. Organoplatinum Compounds / administration & dosage. Time Factors

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037450.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Kumekawa Y, Kaneko K, Ito H, Kurahashi T, Konishi K, Katagiri A, Yamamoto T, Kuwahara M, Kubota Y, Muramoto T, Mizutani Y, Imawari M: Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Gastroenterol; 2006 May;41(5):425-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
  • BACKGROUND: We retrospectively investigated long-term toxicity after concurrent chemoradiotherapy (CRT) for patients with esophageal squamous cell carcinoma (ESCC).
  • Chemotherapy consisted of protracted infusion of 5-fluorouracil 400 mg/m(2) per 24 h on days 1 to 5 and 8 to 12, combined with 2-h infusion of cisplatin 40 mg/m(2) on days 1 and 8.
  • Radiation treatment of the mediastinum at a dose of 30 Gy in 15 fractions was administered concomitantly with chemotherapy.
  • A course schedule with a 3-week treatment and a 2-week break was applied twice, with a total radiation dose of 60 Gy.
  • For the assessment of toxicity, the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation morbidity scoring schema was adopted.
  • RESULTS: A total of 81 patients were recruited in patients with stage I to IVA.
  • CONCLUSIONS: Definitive chemoradiotherapy for ESCC is effective with substantial toxicities.
  • Further investigation is warranted to minimize the normal tissue toxicities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Radiotherapy / adverse effects

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Gastroenterol. 2006 May;41(5):504-6 [16799897.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):18-24 [12556953.001]
  • [Cites] AJR Am J Roentgenol. 1991 Feb;156(2):297-302 [1898802.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1241-7 [1739922.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1118-23 [8501498.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1217-24 [8055441.001]
  • [Cites] Radiology. 1998 Apr;207 (1):123-30 [9530307.001]
  • [Cites] Hum Pathol. 1996 Aug;27(8):766-73 [8760008.001]
  • [Cites] Chest. 1983 Jun;83(6):875-8 [6851689.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2915-21 [10561371.001]
  • [Cites] Eur J Cancer. 1992;28A(8-9):1380-6 [1515254.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1205-11 [7713783.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):447-9 [1905691.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):277-84 [8996153.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923-5 [3466165.001]
  • [Cites] Cancer. 1975 Mar;35(3):795-802 [1111946.001]
  • [Cites] JAMA. 1999 May 5;281(17):1623-7 [10235156.001]
  • [Cites] Chest. 1989 Feb;95(2):388-90 [2914491.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2697-702 [12860946.001]
  • [Cites] Semin Oncol. 1994 Aug;21(4):483-92 [8042046.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):365-70 [2434626.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):29-36 [1704362.001]
  • [Cites] Ann Thorac Surg. 1998 Apr;65(4):1014-9 [9564920.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1167-74 [11870157.001]
  • [Cites] J Clin Oncol. 1990 Apr;8(4):741-50 [2179483.001]
  • [Cites] Radiology. 1983 Feb;146(2):433-8 [6849089.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):622-8 [3559653.001]
  • [Cites] J Clin Oncol. 1984 Feb;2(2):75-9 [6538224.001]
  • (PMID = 16799883.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Isoyama Y, Shioyama Y, Nomoto S, Ohga S, Nonoshita T, Onishi K, Matsuura S, Atsumi K, Terashima K, Hirata H, Honda H: Carboplatin and etoposide combined with radiotherapy for limited-stage small-cell esophageal carcinoma: three cases and review of the literature. Jpn J Radiol; 2010 Apr;28(3):181-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin and etoposide combined with radiotherapy for limited-stage small-cell esophageal carcinoma: three cases and review of the literature.
  • PURPOSE: Small-cell esophageal carcinoma (SCEC) is a rare disease for which standard therapy has not yet been established.
  • We report the results of three cases of limited-stage SCEC treated with combination therapy using carboplatin (CBDCA) and etoposide (VP-16) and radiotherapy.
  • MATERIALS AND METHODS: The clinical stage according to the Japanese Classification of Esophageal Cancer 7th ed. was stage III in 2 cases and stage IVa in 1.
  • These patients with limited-stage SCEC were treated at our institution with four cycles of CBDCA and VP-16, either concurrent with radiotherapy for the second two cycles (n = 2) or followed by radiotherapy after the last cycle (n = 1).
  • Two patients are alive at 16.4 and 22.5 months after initial treatment.
  • One patient died with myeloid leukemia at 43.5 months after initial treatment.
  • Brain metastasis was detected in one patient at 7 months after initial therapy and was treated with stereotactic radiotherapy combined with whole brain irradiation.
  • CONCLUSION: CBDCA and VP-16 in combination with radiotherapy should be considered an important treatment option for SCEC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Combined Modality Therapy. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Middle Aged. Radiation Injuries / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):708-11 [17299393.001]
  • [Cites] Dis Esophagus. 2009;22(2):113-8 [18847450.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1366-72 [9338459.001]
  • [Cites] N Engl J Med. 2007 Aug 16;357(7):664-72 [17699816.001]
  • [Cites] Ann Thorac Surg. 2001 Aug;72(2):596-7 [11515903.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2730-9 [15226341.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3386-91 [9779717.001]
  • [Cites] N Engl J Med. 1999 Aug 12;341(7):476-84 [10441603.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):262-7 [10640955.001]
  • [Cites] Am J Clin Oncol. 2002 Aug;25(4):404-7 [12151974.001]
  • [Cites] Br J Cancer. 2007 Jul 16;97(2):162-9 [17579629.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] Jpn J Clin Oncol. 2008 Jun;38(6):426-31 [18519543.001]
  • [Cites] J Clin Gastroenterol. 1991 Apr;13(2):135-41 [1851772.001]
  • [Cites] J Pathol Bacteriol. 1952 Oct;64(4):889-91 [13000600.001]
  • (PMID = 20437127.001).
  • [ISSN] 1867-108X
  • [Journal-full-title] Japanese journal of radiology
  • [ISO-abbreviation] Jpn J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  • [Number-of-references] 17
  •  go-up   go-down


18. Nishimura Y, Suzuki M, Nakamatsu K, Kanamori S, Yagyu Y, Shigeoka H: Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys; 2002 May 1;53(1):134-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula.
  • PURPOSE: A prospective trial of concurrent chemoradiotherapy (CT-RT) with a protracted infusion of 5-fluorouracil and cisplatin was performed to evaluate the safety and efficacy of this protocol for T4 esophageal cancer (UICC 1997).
  • METHODS AND MATERIALS: Between 1998 and 2000, 28 patients with T4 esophageal squamous cell carcinomas were treated with concurrent CT-RT.
  • Of the 28 patients, 15 had Stage III, 5 Stage IVA, and 8 Stage IV disease.
  • Five of the T4 tumors had evidence of fistula before treatment.
  • Patients received a protracted infusion of 5-fluorouracil 300 mg/m(2)/24 h on Days 1-14, a 1-h infusion of cisplatin 10 mg/body on Days 1-5 and 8-12, and concurrent radiation at a dose of 30 Gy in 15 fractions during 3 weeks.
  • This schedule was repeated twice, with a 1-week split, for a total RT dose of 60 Gy during 7 weeks for 25 patients.
  • For the remaining 3 patients, 30 Gy of preoperative CT-RT was administered.
  • RESULTS: Of the 25 patients who were treated with the full dose of CT-RT, 14 (56%) completed the two courses of the CT-RT protocol, and 8 patients (32%) received the full dose of RT but a reduced dose of chemotherapy.
  • However, the worsening or development of an esophageal fistula was noted in 5 patients.
  • The 2-year survival rate for patients with Stage III was 27%, and the median survival time for those with Stage III and Stage IVA+IV was 12 and 5 months, respectively.
  • CONCLUSION: Despite its significant toxicity for esophageal fistula, this concurrent CT-RT protocol of protracted 5-fluorouracil infusion and cisplatin appears feasible and effective for T4 esophageal cancer with or without fistulas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Esophageal Fistula / complications. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12007951.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Lü JM, Liang J, Wang JW, He J, Xiao ZF, Zhang HX, Chen DF, Feng QF, Wang LH: [Clinical analysis of 126 patients with primary small cell carcinoma of the esophagus]. Zhonghua Zhong Liu Za Zhi; 2009 Feb;31(2):121-5
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 126 patients with primary small cell carcinoma of the esophagus].
  • OBJECTIVE: To investigate the prognostic factors and the principles of treatment of primary esophageal small cell carcinoma (SCEC) retrospectively.
  • 85 patients were in limited disease stage (LD) and 41 patients as extensive disease stage (ED) according to the Veterans Administration Lung Study Group staging system.
  • Among the 84 patients treated with esophagectomy, 8 cases were in stage I, 16 in stage IIa, 10 in stage IIb, 40 in stage III, 4 in stage IVa and 6 in stage IVb, according to the TNM system (6(th) edition, AJCC).
  • The 1-, 3-, and 5-year overall survival rates (OS) were 52.2%, 15.9%, and 12.2%, respectively, with a median survival time (MST) of 12.5 months.
  • The MST of the patients treated with chemotherapy was 14.5 months, significantly longer than the 5.2 months of the patients without (P = 0.0001).
  • Multivariate analysis showed that stage (HR 1.91, 95% CI 1.26 approximately 2.91, P = 0.002), length of the primary lesion (HR 1.75, 95% CI 1.17 approximately 2.63, P = 0.007), and chemotherapy (HR 0.42, 95% CI 0.28 approximately 0.65, P = 0.000) were independent prognostic factors.
  • CONCLUSION: Esophageal small cell carcinoma is a systemic disease.
  • The tumor stage (LD or ED), length of the primary lesion and chemotherapy are independent prognostic factors.
  • Therefore, a systemic therapy based on chemotherapy should be recommended.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / therapy. Esophageal Neoplasms / therapy. Esophagectomy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, High-Energy. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538888.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Nemoto K, Ogawa Y, Matsushita H, Takeda K, Takahashi C, Saito H, Takai Y, Yamada S, Hosoi Y: A pilot study of radiation therapy combined with daily low-dose cisplatin for esophageal cancer. Oncol Rep; 2001 Jul-Aug;8(4):785-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of radiation therapy combined with daily low-dose cisplatin for esophageal cancer.
  • From March 1992 to October 1997, a total of 38 patients with histologically proven esophageal cancer received combination therapy of daily low-dose cisplatin (CDDP) and radiation therapy.
  • The clinical stages (UICC 1997) were I in 3, IIA,B in 13, III in 13, and IVA in 9 patients.
  • All patients received at least 60 Gy of radiation therapy.
  • Of the 38 patients, 14 patients completed full course of chemoradiation therapy.
  • Survival of the stage II-IVA patients who received daily low-dose CDDP and radiation therapy was a little better than that of historical control patients who were treated by radiation therapy alone.
  • Although the results indicate that daily low-dose CDDP combined with radiation therapy may slightly improve the survival of esophageal cancer patients with acceptable toxicity, further efforts should be made to optimize clinical trial protocols.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Radiotherapy Dosage. Survival Rate. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11410784.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Sato Y, Takayama T, Sagawa T, Okamoto T, Miyanishi K, Sato T, Araki H, Iyama S, Abe S, Murase K, Takimoto R, Nagakura H, Hareyama M, Kato J, Niitsu Y: A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer. Cancer Chemother Pharmacol; 2006 Nov;58(5):570-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
  • PURPOSE: To determine the recommended dose (RD) of cis-diammine-glycolatoplatinum (nedaplatin) when given concurrently with 5-FU and high dose radiation therapy in the treatment of esophageal cancer.
  • METHODS: Twenty-six patients with clinical stage I to IVA squamous cell carcinoma of the esophagus were enrolled in a non-surgical treatment comprised of a fixed dose of fluorouracil (400 mg/m2 administered as continuous intravenous infusion on days 1-5 and days 8-12) plus escalating doses of nedaplatin (40 mg/m2 in level 1, 50 mg/m2 in level 2, or 60 mg/m2 in level 3 on days 1 and 8), repeated twice every 3 weeks with concurrent radiotherapy (60 Gy).
  • The 1- and 3-year survival rates were 65.1 and 37.2%, respectively, with a median survival time of 21.2 months.
  • CONCLUSIONS: The combination of nedaplatin and 5-FU with radiation is a feasible regimen that shows promising antitumor activity with an acceptable safety profile in patients with esophageal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / therapy. Radiotherapy, Adjuvant / methods
  • [MeSH-minor] Aged. Anemia / chemically induced. Dose-Response Relationship, Drug. Esophagitis / chemically induced. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Infusions, Intravenous. Male. Middle Aged. Nausea / chemically induced. Neutropenia / chemically induced. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Remission Induction. Severity of Illness Index. Survival Rate. Thrombocytopenia / chemically induced. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16463059.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Nakamura M, Maruyama K, Furukawa J, Maruyama N, Shingai T, Katsumoto Y, Nakaguchi K, Okajima S, Sue F, Morimoto T: [A patient with esophageal cancer with subcutaneal abscess and esophago-tracheal fistula who survived more than 2 years following treatment by drainage and chemoradiation therapy]. Gan To Kagaku Ryoho; 2001 Oct;28(11):1662-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with esophageal cancer with subcutaneal abscess and esophago-tracheal fistula who survived more than 2 years following treatment by drainage and chemoradiation therapy].
  • A diagnosis of esophageal cancer with subcutaneous abscess was made based on examination and biopsy results.
  • The cancer was Ce T4NxMx Stage III-IVa.
  • Curative surgery was considered impossible, so chemoradiation therapy was performed (5-FU 500 mg + CDDP 5 mg/day + 2 Gy/day x 31 days) after drainage.
  • During the therapy, an esophago-tracheal fistula was observed, but it later vanished.
  • After chemoradiation therapy, the abscess and tumor vanished.
  • Now, 2 years after therapy, no recurrence has been found.
  • Chemoradiation therapy is effective for inoperable advanced esophageal cancer.
  • [MeSH-major] Abscess / etiology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Skin Diseases, Infectious / etiology. Tracheoesophageal Fistula / etiology


23. Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC: Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients. Radiother Oncol; 2009 Jul;92(1):100-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients.
  • PURPOSE: To retrospectively analyze the outcome of patients with anaplastic thyroid carcinoma (ATC) treated in the Erasmus MC.
  • Tumor stage was IVA in 9%, IVB in 51%, and IVC in 40%.
  • Before 1988 adjuvant treatment consisted of conventional radiotherapy (RT) and/or chemotherapy (CT).
  • This consists of locoregional RT in 46 fractions of 1.1 Gy, given twice daily, followed by prophylactic irradiation of the lungs (PLI) in 5 daily fractions of 1.5 Gy.
  • Acute toxicity in the protocol group was significantly higher than in the nonprotocol group, with 46% versus 11% grade 3 pharyngeal and/or esophageal toxicity.
  • CONCLUSION: Despite the ultimately dismal prognosis of ATC-patients, multimodality treatment significantly improved local control and improved the median survival.
  • [MeSH-major] Carcinoma / therapy. Neoplasm Recurrence, Local. Thyroid Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19328572.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


24. Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, Muto M, Ogino T, Yoshida S: Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol; 2003 Jul 15;21(14):2697-702
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus.
  • PURPOSE: To assess the long-term toxicity after definitive chemoradiotherapy (CRT) for squamous cell carcinoma (SCC) of the esophagus.
  • PATIENTS AND METHODS: Patients newly diagnosed with SCC of the esophagus and treated with definitive CRT between 1992 and 1999 in our institution were recruited from our database on the basis of the following criteria: age </= 75 years, performance status (PS; based on the Eastern Cooperative Oncology Group scale) 0 to 2, and clinical tumor-node-metastasis system stage I to IVA.
  • The CRT consisted of two cycles of cisplatin 40 mg/m2 on days 1 and 8, and continuous infusion of fluorouracil 400 mg/m2/d on days 1 to 5 and 8 to 12, repeated every 5 weeks with concurrent radiotherapy of 60 Gy in 30 fractions.
  • For the assessment of toxicity, the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme was adopted.
  • With a median follow-up of 53 months, the median survival time and 5-year survival rate were 21 months and 29%, respectively.
  • CONCLUSION: Definitive CRT for SCC of the esophagus is effective with substantial toxicities.
  • Additional investigation to minimize the normal tissue toxicities is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Brachytherapy / adverse effects. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / mortality. Esophageal Neoplasms / therapy. Maximum Tolerated Dose
  • [MeSH-minor] Adult. Aged. Cohort Studies. Combined Modality Therapy / adverse effects. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiation Injuries / mortality. Radiotherapy Dosage. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Thorax. Time Factors






Advertisement